Palisade Bio (PALI) Treasury Shares (2012 - 2025)

Palisade Bio (PALI) reported Treasury Shares of $24.8 million for Q4 2025, up 102593.12% quarter-over-quarter from $24195.0 in Q4 2023.

Palisade Bio (PALI) Treasury Shares (2012 - 2025) Analysis & Trends

Palisade Bio (PALI) has 10 years of Treasury Shares data on file, last reported at $24.8 million in Q4 2025.

Treasury Shares for Q4 2025 came in at $24.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $24.8 million (changed N/A YoY), and the FY2025 annual result was $24.8 million, changed N/A from the prior year.
Treasury Shares grew to $24.8 million in Q4 2025 per PALI's latest filing, from $24195.0 in the prior quarter.
Over five years, Treasury Shares peaked at $24.8 million in Q4 2025 and troughed at $8817.0 in Q2 2021.
A 3-year average of $4.3 million and a median of $141857.0 in 2023 frame the typical range for Treasury Shares.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	1.48 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	700,000.00
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Palisade Bio	391.02 Mn	261.45 Mn	-	-

Download Data